Related Experiment Video
Updated: Jun 5, 2026
08:04
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
Plasma proteome predicts chemotherapy response in osteosarcoma patients
Yiting Li1, Tu Anh Dang, Jianhe Shen
1Texas Children's Cancer Center, Texas Children's Hospital, and Department of Pediatrics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
Oncology Reports
|December 18, 2010
Summary
Researchers developed a blood test to predict chemotherapy response in osteosarcoma patients. This test identifies poor responders early, enabling personalized treatment strategies and potentially improving outcomes for children and young adults.
Area of Science:
- Oncology
- Proteomics
- Biomarker Discovery
Background:
- Osteosarcoma is a common bone cancer in children and young adults.
- Chemotherapy resistance is a major factor impacting patient prognosis.
- Current methods for assessing chemotherapy response lack predictive power at diagnosis.
Purpose of the Study:
- To identify plasma proteomic profiles that can distinguish between good and poor responders to chemotherapy before treatment.
- To develop a predictive tool for personalized osteosarcoma treatment strategies.
Main Methods:
- Analysis of plasma proteomic profiles from osteosarcoma patients before and after chemotherapy.
- Utilized a linear support vector machine algorithm with cross-validation.
- Identified and validated specific plasma proteins as biomarkers.
Main Results:
- Developed classifiers accurately predicting chemotherapy response (85% accuracy) in both pre- and post-treatment plasma samples.
- Identified serum amyloid protein A and transthyretin as key proteins in the predictive classifiers.
- Demonstrated that plasma proteomic profiles can predict treatment response prior to therapy initiation.
Conclusions:
- Plasma proteomic profiles can accurately predict chemotherapy response in osteosarcoma patients before treatment.
- This predictive capability may lead to a simple blood test for personalized medicine.
- The identified proteins' involvement in innate immunity suggests potential therapeutic targets for enhancing anti-tumor activity.
